A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here

Monday 18 July 2011

Escitalopram in France

On Friday Chris Hayes (Lundbeck) furnished The SPC Blog with an English-language translation of the Austrian Supreme Court’s ruling concerning an SPC for Escitalopram (17 Ob 5/11a).  Today we have further reason to thank Chris: he has also let us have this translation of another decision involving Escitalopram -- this time from the Tribunal de Grande Instance (first instance court) de Paris, dated 30 September 2010.

The decision relates both to the patent and the SPC and, Chris explains, the SPC part of the judgment raises some interesting points about the interplay of the SPC Regulations and other pharma regs.

No comments: